Moderna Shares Crater on Huge Revenue Miss, Massive Guidance Cut

Vaccine giant's shares plunge 10% amid reports of rare side effects, new government restrictions, production struggles

Image Credits: Moch Farabi Wardana/Pacific Press/LightRocket via Getty Images.

Moderna has just reported its Q3 earnings Thursday, revealing a massive miss on Wall Street’s revenue expectations by more than $1 billion, as well as sales guidance that spooked the Street.

The news sent Moderna shares down more than 10% amid reports of rare side effects, new government restrictions and vaccine production struggles.

Shares of the vaccine-making giant led its rivals lower Thursday, as Pfizer, BioNTech and Novavax were all in the red in premarket trading.

Moderna’s quarterly revenue came in at $4.97BN, compared with the Wall Street estimate of estimate $6.32BN. Of course, YoY sales have exploded since last year, which was before the US and European governments approved the company’s vaccine for widespread use (Moderna only reported $157.9MM in Q32020 billion. Sales estimates ranged from $4.94 billion to $7.37 billion, according to Bloomberg. The company’s guidance for full-year 2021 sales also missed the average analyst estimates.

Here’s a breakdown of the Q3 earnings courtesy of Bloomberg:

  • Covid-19 vaccine revenue $4.81 billion, +15% q/q, estimate $6.27 billion
  • Revenue $4.97 billion vs. $157.9 million y/y, estimate $6.32 billion (range $4.94 billion to $7.37 billion)
  • Collaboration rev. $19 million, +56% y/y, estimate $19.3 million
  • Grant revenue $140 million, -3.9% y/y, estimate $172.5 million
  • EPS $7.70 vs. loss/share 59.00c y/y
  • Total operating expenses $1.41 billion vs. $393.0 million y/y, estimate $1.49 billion
  • R&D expenses $521 million, +51% y/y, estimate $478.1 million
  • Operating profit $3.56 billion vs. loss $235.1 million y/y
  • Cash and other $15.35 billion

Additionally, Moderna says it has $17 billion of signed vaccine orders for 2022, and expects sales in the range of $17 billion to $22 billion. But investors apparently still have serious questions about the long-term outlook for sales as the number of booster jabs people will receive remains uncertain, while Pfizer raised its full-year guidance earlier this week, impressing analysts and further cementing Moderna’s burgeoning rep as the second-fiddle player in the mRNA vaccine market.

Prince Charles is taking control of the British Empire and has declared war to enforce the ‘Great Reset’ lockdown of society.



WATCH ALL SHOWS

AUDIO